Clinical Trial Update: Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects [Phase 1]

View source ↗

Summary

Phase 1 trial of inhaled molgramostim (rhGM-CSF) in healthy adults has completed, evaluating safety and tolerability for potential pulmonary diseases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchiectasis
• Cystic Fibrosis
• Pulmonary Alveolar Proteinosis
• Respiratory Distress Syndrome

Drugs mentioned

• Molgramostim (granulocyte-macrophage colony-stimulating factor (GM-CSF))

Snippet

Sponsor: Savara Inc. | Conditions: Pulmonary Alveolar Proteinosis, Bronchiectasis | Phase 1 | Status: COMPLETED